Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 9/20 | 0.60 |
| ▸ | NOS1 | P29475 | 5/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PAH | P00439 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PNP | P00491 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycidol SCHEMBL9761361 | 0.88 | HPRT1 (0.59) | HPRT1NOS1NOS3NOS2PNP | |
| SCHEMBL21637016 | 0.86 | HPRT1 (0.57) | HPRT1NOS1NOS3NOS2PNP | |
| SCHEMBL3836268 | 0.85 | HPRT1 (0.61) | HPRT1NOS1NOS3NOS2PNP | |
| SCHEMBL3743947 | 0.84 | HPRT1 (0.56) | HPRT1NOS1NOS3NOS2USP2 | |
| SCHEMBL571646 | 0.84 | HPRT1 (0.60) | HPRT1NOS1PNP | |
| SCHEMBL8149575 | 0.84 | HPRT1 (0.60) | HPRT1NOS1NOS3NOS2USP2 | |
| SCHEMBL1672180 | 0.84 | HPRT1 (0.56) | HPRT1NOS1NOS3NOS2USP2 | |
| SCHEMBL7745028 | 0.83 | HPRT1 (0.64) | HPRT1NOS1USP2CASP7HSD17B10 | |
| SCHEMBL10506465 | 0.83 | HPRT1 (0.53) | HPRT1NOS1NOS3NOS2USP2 | |
| SCHEMBL10506166 | 0.83 | HPRT1 (0.53) | HPRT1NOS1NOS3NOS2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11382919-B2 | Prevention and treatment of viral infections | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2022-07-12 | — | — | US | disclosed |
| US-20200383994-A1 | PREVENTION AND TREATMENT OF VIRAL INFECTIONS | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2020-12-10 | — | — | US | disclosed |
| US-9333219-B2 | Method to treat or prevent herpesvirus infections | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150190419-A1 | METHOD TO TREAT OR PREVENT HERPESVIRUS INFECTIONS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2015-07-09 | — | — | US | disclosed |
| WO-2014022185-A2 | METHOD TO TREAT OR PREVENT HERPESVIRUS INFECTIONS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2014-02-06 | — | — | WO | disclosed |
| US-5175151-A | Useful for treating herpes group viruses | SCHERING CORPORATION (US) | 1992-12-29 | — | — | US | disclosed |
| US-4360522-A | VIRICIDES | BURROUGHS WELLCOME CO. (US) | 1982-11-23 | — | — | US | disclosed |
| US-4323573-A | VIRICIDES | BURROUGHS WELLCOME CO. (US) | 1982-04-06 | — | — | US | disclosed |
| US-4294831-A | ANTIVIRAL ACTIVITY | BURROUGHS WELLCOME CO. (US) | 1981-10-13 | — | — | US | disclosed |
| US-4287188-A | PARTICULARLY 9-(2-HYDROXYETHOXYMETHYL) GUANINE MONOPHOSPHATE AND SALTS, USEFUL AS ANTIVIRIAL AGENTS | BURROUGHS WELLCOME CO. (US) | 1981-09-01 | — | — | US | disclosed |
| US-4199574-A | Methods and compositions for treating viral infections and guanine acyclic nucleosides | BURROUGHS WELLCOME CO. (US) | 1980-04-22 | — | — | US | disclosed |
| US-4146715-A | ANTIVIRAL AGENTS | BURROUGHS WELLCOME CO. (US) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11382919-B2 | Prevention and treatment of viral infections | SMPD1, PTDSS1, PHOSPHO1 | HPRT1 1687/4885NOS1 2854/4885NOS3 3023/4885 |
| US-20200383994-A1 | PREVENTION AND TREATMENT OF VIRAL INFECTIONS | SMPD1, PTDSS1, PHOSPHO1 | HPRT1 1687/4885NOS1 2854/4885NOS3 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.